Trials / Conditions / Recurrent Peripheral Primitive Neuroectodermal Tumor

Recurrent Peripheral Primitive Neuroectodermal Tumor

9 registered clinical trials studyying Recurrent Peripheral Primitive Neuroectodermal Tumor — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702	St. Jude Children's Research Hospital	Phase 1 / Phase 2
Active Not Recruiting	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994	National Cancer Institute (NCI)	Phase 2
Completed	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250	National Cancer Institute (NCI)	Phase 2
Completed	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678	National Cancer Institute (NCI)	Phase 2
Completed	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620	National Cancer Institute (NCI)	Phase 2